Drug Treatment Effects on Disease Progression
- 1 April 2001
- journal article
- review article
- Published by Annual Reviews in Annual Review of Pharmacology and Toxicology
- Vol. 41 (1), 625-659
- https://doi.org/10.1146/annurev.pharmtox.41.1.625
Abstract
Degenerative diseases are characterized by a worsening of disease status over time. The rate of deterioration is determined by the natural rate of progression of the disease and by the effect of drug treatments. A goal of drug treatment is to slow disease progression. Drug treatments can be categorized as symptomatic or protective. Symptomatic treatments do not affect the rate of disease progression whereas protective treatments have the ability to slow disease progression down. Many current methods for describing disease progression have two common drawbacks: a linear relationship between time and disease status is assumed, and within- and between-subject variability is ignored. Disease progress models combined with pharmacokinetic pharmacodynamic models and hierarchical random effects statistical models provide insights into understanding the time course and management of degenerative disease.Keywords
This publication has 95 references indexed in Scilit:
- Simulation of Clinical TrialsAnnual Review of Pharmacology and Toxicology, 2000
- Mortality in DATATOP: A Multicenter trial in early Parkinson's diseaseAnnals of Neurology, 1998
- Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal WomenThe New England Journal of Medicine, 1997
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseThe New England Journal of Medicine, 1993
- An Interim Report of the Effect of Selegiline (L -Deprenyl) on the Progression of Disability in Early Parkinson’s DiseaseEuropean Neurology, 1992
- AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITYBrain, 1991
- A simulation study comparing designs for dose rangingStatistics in Medicine, 1991
- Response to a Standard Oral Levodopa Test in Parkinsonian Patients with and without Motor FluctuationsClinical Neuropharmacology, 1990
- Nigrostriatal function in humans studied with positron emission tomographyAnnals of Neurology, 1989
- Computer simulation as a tool for clinical trial designInternational Journal of Bio-Medical Computing, 1979